» Articles » PMID: 38542025

His Bundle Pacing: Predicting Mortality and Major Complications in Mid-Term Follow-Up

Overview
Journal J Clin Med
Specialty General Medicine
Date 2024 Mar 28
PMID 38542025
Authors
Affiliations
Soon will be listed here.
Abstract

: His bundle pacing (HBP) is suitable for 80% of patients with any indication for permanent pacemaker implantation, with a clinical benefit compared to right ventricular pacing (RVP). Although complications and mortality related to RVP are widely reported in the literature, data on HBP are limited. This study aimed to analyze HBP complications and outcomes in the short-term (up to 30 days) and long-term (up to the following 24 months) follow-up (F/U). : The study includes 373 patients aged ≥ 18, enrolled from October 2015 to May 2019 in a single-center HBP prospective registry conducted in the Department of Electrocardiology, Upper Silesian Medical Centre of the Medical University of Silesia in Katowice, Poland. Mortality and HBP complications were used as end-points: during hospitalization and up to 30 days (short-term F/U), and for each F/U point-six months, 12 months, and 24 months after the procedure (long-term F/U). : Successful HBP was achieved in 252 patients (68%), with an increasing success rate during consecutive years: 57% in 2015-2016 and 73% in 2017-2019. Complications were found in 8.4% of patients (21/252) in short-term F/U and 5.8% (13/224), 5.5% (11/201), and 6.9% (12/174) at six months, 12 months, and 24 months, respectively. There were no deaths during the first 30 days. However, 26 patients (10.3%) died within 24 months. A left ventricular ejection fraction (LVEF) ≤ 34% was the only independent predictor of all-cause mortality or any major complication in the 24-month F/U. : This single-center study reported a low risk of mortality and complications associated with HBP at the short-term F/U. However, during the long-term F/U, we observed a higher but acceptable risk of major complications, with a lower LVEF being an independent predictor of the composite end-point of all-cause mortality or any major complication.

Citing Articles

Current Advance, Challenges and Future Perspectives of Conduction System Pacing.

Wang T, Ma P, Yang Y, Xia Y, Jing Z, She Z Rev Cardiovasc Med. 2025; 25(12):438.

PMID: 39742235 PMC: 11683707. DOI: 10.31083/j.rcm2512438.


Left bundle branch-optimized cardiac resynchronization therapy upgrade in a patient with previous percutaneous edge-to-edge tricuspid valve repair and indirect mitral valve annuloplasty.

Aschacher T, Pichler G, Derndorfer M, Tauber S, Grabenwoger M HeartRhythm Case Rep. 2024; 10(10):729-733.

PMID: 39664843 PMC: 11628801. DOI: 10.1016/j.hrcr.2024.07.010.

References
1.
Peterson P, Daugherty S, Wang Y, Vidaillet H, Heidenreich P, Curtis J . Gender differences in procedure-related adverse events in patients receiving implantable cardioverter-defibrillator therapy. Circulation. 2009; 119(8):1078-84. DOI: 10.1161/CIRCULATIONAHA.108.793463. View

2.
cikes M, Solomon S . Beyond ejection fraction: an integrative approach for assessment of cardiac structure and function in heart failure. Eur Heart J. 2015; 37(21):1642-50. DOI: 10.1093/eurheartj/ehv510. View

3.
Kirkfeldt R, Johansen J, Nohr E, Jorgensen O, Nielsen J . Complications after cardiac implantable electronic device implantations: an analysis of a complete, nationwide cohort in Denmark. Eur Heart J. 2013; 35(18):1186-94. PMC: 4012708. DOI: 10.1093/eurheartj/eht511. View

4.
Nowak B, Misselwitz B, Erdogan A, Funck R, Irnich W, Israel C . Do gender differences exist in pacemaker implantation?--results of an obligatory external quality control program. Europace. 2009; 12(2):210-5. DOI: 10.1093/europace/eup312. View

5.
Khurshid S, Epstein A, Verdino R, Lin D, Goldberg L, Marchlinski F . Incidence and predictors of right ventricular pacing-induced cardiomyopathy. Heart Rhythm. 2014; 11(9):1619-25. DOI: 10.1016/j.hrthm.2014.05.040. View